Ex-No­var­tis CEO Joe Jimenez is tak­ing an­oth­er crack at open­ing a new chap­ter in his ca­reer — and that in­cludes a new board seat and a $250M start­up

Joe Jimenez is back.

The ex-CEO of No­var­tis has tak­en a board seat on Cen­tu­ry Ther­a­peu­tics, the Ver­sant and Bay­er-backed start­up fo­cused on com­ing up with a brand new twist on cell ther­a­pies for can­cer — a field where Jimenez made his mark back­ing the first per­son­al­ized CAR-T ap­proved for use.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN